{"id":"W4410312427","doi":"10.1093/oncolo/oyaf048","title":"Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; Genentech; Astellas Pharma; Oncolytics Biotech; Eisai; Les Laboratories Pierre Fabre; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; F. Hoffmann-La Roche; Chugai Pharmaceutical; Seagen; Roche; GlaxoSmithKline; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Nausea; Internal medicine; Trastuzumab; Chemotherapy; Oncology; Hazard ratio; Adverse effect; Quality of life (healthcare); Cohort; Cancer; Breast cancer; Confidence interval","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002784753,0.0003877516,0.0008575395,0.0002227122,0.000164179,0.0005468248,0.0003345413,0.0005228987,0.001545544],"category_scores_gemma":[0.002303722,0.000115711,0.001392621,0.0003127243,0.0003563484,0.0003531744,0.0003277067,0.0008910422,0.0001113254],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000642065,"about_ca_system_score_gemma":0.0004603331,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000516721,"about_ca_topic_score_gemma":0.0008057914,"domain_scores_codex":[0.9990047,0.0006693366,0.00004957453,0.0000889586,0.0000982338,0.00008931274],"domain_scores_gemma":[0.997934,0.0008710149,0.0007233532,0.00006818621,0.00006181556,0.0003417016],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8169683,0.005415112,0.1141734,0.0005643992,0.002971946,0.0001025554,0.0001290553,0.002683134,0.002079537,0.0001290507,0.001039938,0.05374351],"study_design_scores_gemma":[0.1859663,0.3476336,0.4484655,0.0001928231,0.005285608,0.0004453038,0.0001933281,0.005788445,0.002937492,0.0005327937,0.002496228,0.00006259368],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977899,0.001470413,0.00005791861,0.0001151791,0.00002050996,0.00004570641,0.0001760684,0.000002918975,0.0003214531],"genre_scores_gemma":[0.9990282,0.0003426179,0.00006442605,0.00009220652,0.00004428516,0.00005858136,0.0002643037,0.000001003992,0.0001044093],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002784753,"threshold_uncertainty_score":0.01472741,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01682158196963432,"score_gpt":0.3043310066982524,"score_spread":0.2875094247286181,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}